Primary therapy of adult patients with Burkitt lymphoma in The Netherlands. (A) Application of primary therapy among 990 patients diagnosed between 1989 and 2018 according to the 3 broadly defined categories of primary therapy. The absolute number of patients within a specific calendar period and age group in panel A is shown in supplemental Table 3. The proportion of rituximab added to chemotherapy among patients diagnosed during 2009 to 2018 is shown in supplemental Table 4 according to age at diagnosis. (B) Application of primary therapy among 170 patients (median age, 59 years; interquartile age range, 44-70 years; 79% males; and 87% stage III-IV) diagnosed between 2014 and 2018 according to the exact therapeutic regimen, stratified by age at diagnosis. The absolute number of patients within a specific age and treatment group in panel B is shown in supplemental Table 5. Of note, 17 (10%) of 170 patients diagnosed between 2014 and 2018 received a variety of regimens. These exact regimens are presented in supplemental Table 6. DA, dose-adjusted; EPOCH-R, rituximab with etoposide, vincristine, and doxorubicin; R-IVAC, rituximab, ifosfamide, etoposide, and high-dose cytarabine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CODOX-M, rituximab, cyclophosphamide, doxorubicin, vincristine, and methotrexate; SCT, stem cell transplantation.